## Roger Prades

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1424417/publications.pdf

Version: 2024-02-01

1937457 1872570 6 159 4 6 citations h-index g-index papers 6 6 6 278 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The matrix metalloproteinase inhibitor IPR-179 has antiseizure and antiepileptogenic effects. Journal of Clinical Investigation, 2021, 131, .	3.9	35
2	Design and synthesis of selective and blood-brain barrier-permeable hydroxamate-based gelatinase inhibitors. Bioorganic Chemistry, 2020, 94, 103365.	2.0	14
3	Development of Innovative Antiatherosclerotic Peptides through the Combination of Molecular Modeling and a Dual (Biochemicalâ€Cellular) Screening System. Advanced Therapeutics, 2020, 3, 2000037.	1.6	2
4	Molecular basis for the protective effects of low-density lipoprotein receptor-related protein 1 (LRP1)-derived peptides against LDL aggregation. Biochimica Et Biophysica Acta - Biomembranes, 2019, 1861, 1302-1316.	1.4	10
5	Applying the Retroâ€Enantio Approach To Obtain a Peptide Capable of Overcoming the Blood–Brain Barrier. Angewandte Chemie - International Edition, 2015, 54, 3967-3972.	7.2	96
6	Does the Solid-Phase Synthesis of a Tetrapeptide Represent a Challenge at the Onset of the XXI Century? The Case of Cyclo [(3R)-3-hydroxydecanoyl-l-seryl-(3R)-3-hydroxydecanoyl-l-seryl]. International Journal of Peptide Research and Therapeutics, 2007, 13, 313-327.	0.9	2